Insmed, Inc. $INSM Shares Newly Bought by Machina Capital S.A.S.

Machina Capital S.A.S. purchased a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,087 shares of the biopharmaceutical company’s stock, valued at approximately $2,179,000.

Several other large investors also recently bought and sold shares of the business. C WorldWide Group Holding A S increased its position in Insmed by 62.1% during the second quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock valued at $27,840,000 after acquiring an additional 100,000 shares during the last quarter. Empowered Funds LLC increased its position in Insmed by 32.6% in the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock worth $8,501,000 after buying an additional 12,775 shares in the last quarter. Motley Fool Asset Management LLC purchased a new stake in Insmed in the third quarter worth about $2,034,000. S&CO Inc. bought a new position in shares of Insmed in the second quarter worth about $1,386,000. Finally, Nykredit A S bought a new stake in Insmed during the 2nd quarter worth approximately $10,997,000.

Insmed Price Performance

Shares of INSM stock opened at $118.07 on Friday. The company’s 50-day simple moving average is $110.93 and its two-hundred day simple moving average is $123.57. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The firm’s revenue was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.75) earnings per share. On average, sell-side analysts anticipate that Insmed, Inc. will post -1.86 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on INSM shares. Stifel Nicolaus set a $195.00 price target on Insmed in a report on Thursday, October 29th. Truist Financial reaffirmed a “buy” rating and set a $195.00 price target (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Evercore reaffirmed an “outperform” rating and issued a $170.00 price objective on shares of Insmed in a research note on Friday, August 7th. Bank of America reiterated a “buy” rating and issued a $207.00 target price on shares of Insmed in a report on Monday, October 12th. Finally, Wells Fargo & Company increased their price target on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $196.52.

Insider Buying and Selling at Insmed

In related news, Director David Brennan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.